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Abstract: The science and policy of pharmaceuticals produced and/or delivered by plants 
has evolved over the past twenty-one years from a backyard remedy to regulated, purified 
products.  After  seemingly  frozen  at  Phase  I  human  clinical  trials  with  six  orally  
delivered plant-made vaccines not progressing past this stage over seven years, plant-made 
pharmaceuticals  have  made  a  breakthrough  with  several  purified  plant-based  products 
advancing to Phase II trials  and beyond. Though fraught  with the usual difficulties  of 
pharmaceutical  development,  pharmaceuticals  made  by  plants  have  achieved  pertinent 
milestones albeit slowly compared to other pharmaceutical production systems and are 
now at the cusp of reaching the consumer. Though the current economic climate begs for 
cautious investment as opposed to trail blazing, it is perhaps a good time to look to the 
future  of  plant-made  pharmaceutical  technology  to  assist  in  planning  for  future 
developments in order not to slow this technology’s momentum. To encourage continued 
progress, we highlight the advances made so far by this technology, particularly the change 
in paradigms, comparing developmental timelines, and summarizing the current status and 
future possibilities of plant-made pharmaceuticals. 
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1. Introduction  
Vaccine development has advanced immensely over the last century. While conventional vaccines 
have reduced the burden of many life-threatening diseases, alternative methods for vaccine production 
have  aimed  to  improve  the  number  of  diseases  protected  against,  the  quality  and  efficacy  of  the 
vaccines and their availability to a greater audience, especially to the less-privileged [1–3]. Several 
systems including E. coli, yeast, mammalian cells and insect cells, have been utilized for vaccine 
production. Each one has advantages and shortcomings with respect to recombinant protein production 
and a new vaccine candidate is often run through a battery of host production systems to determine the 
optimal one for expression.  
Close to 21 years ago, transgenic plants were proposed as an alternative production system for 
pharmaceutical protein, with cited advantages of decreased cost, increased ease of delivery and scale 
up, and decreased risk of contamination with animal and human pathogens. We review the evolution 
of whole plants and plant cells as pharmaceutical production systems, highlighting shifting paradigms, 
comparing the timeline of development to competing production systems, and summarizing the current 
status and future possibilities of plant-made pharmaceuticals. 
2. Development of the Plant-Made Vaccine Paradigm 
In the early 1990s, three main groups were working to prove the concept of plant-made vaccines. 
The  groups  were  all  within  academia  and  were  under  the  tutelage  of  Charles  Arntzen,  Hilary 
Koprowski  and  Roy  Curtiss.  While  the  research  of  Dr. Arntzen’s  group  resulted  in  the  first  peer 
reviewed paper [4] Dr. Curtiss’s research resulted in the first patent [5] (Figure 1). At this early ―edible 
vaccine‖ stage, it was proposed that antigen-producing fruit or vegetables would deliver vaccines in a 
safe  and  cost-effective  manner,  as  well  as  increase the  frequency  of  childhood  vaccinations. In  a 
competitive market with established production methods, the concept of using plants as an alternative 
vaccine source was not unrealistic and the prospect of using edible plant material to express and 
deliver vaccines was novel and appealing. It was proposed that the plants could be grown close to 
target populations using local farming techniques, and that this method would result in a cheap and 
easy mode of vaccination. It was thought that edible vaccines would reduce the cost of vaccination by 
cutting  down  on  costs  associated  with  transport,  production,  purification  and  other  downstream 
processes  used  by  conventional  vaccines.  Added  to  this  was  the  advantage  of  eliciting  mucosal 
immune  response  from  the  gastrointestinal  tract,  the  site  of  entry  of  many  pathogens.  The  basic 
concept of edible vaccines involved eating a piece of antigen containing fruit or vegetable to become 
vaccinated.  However,  this  idea  had  several  drawbacks,  including  difficulties  in  standardizing  the 
vaccine  dose  and  issues  regarding  the  regulation  of  transgenic  plants  with  added  concerns  of 
contaminating  the  food  chain.  This  issue  was  highlighted  by  the  ―StarLink  Affair‖  where  
non-genetically modified (GM) corn destined for human consumption was contaminated with a GM 
variety that had been approved for animal use but not human. Although the company was ordered to 
perform  an  extensive  cleanup,  the  incident  reflected  poorly  on  the  idea  of  food  crops  producing 
antigens [6].  Int. J. Mol. Sci. 2011, 12                    
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Figure 1. Comparison of the development of recombinant protein production systems. 
 Proposals soon followed that the transgenic plants producing pharmaceuticals should be grown in contained systems such as greenhouses; in a plot 
isolated from general food crops; and/or engineered to be male sterile [1,7]. Administration of vaccines resulting from such plants was to be medically 
supervised. Despite positive research outcomes, another limitation to using edible vaccines was soon identified. The expression of the antigen varied 
greatly between different species and even from fruit to fruit and leaf to leaf within the same plant, making standardized delivery all but impossible. With 
the realization of these shortcomings, the initial edible vaccine paradigm consisting of vaccine-delivering produce shifted. The second iteration of  
plant-derived vaccines involved the use of plants expressing a vaccine antigen; however instead of ingesting the edible plant product in its basic state, the 
plant material was to be minimally processed, possibly through freeze drying, grinding and pooling to create a batch of homogenous antigen concentration 
to control dosage. This preparation could then be administered mixed in liquid that could be ingested under medical supervision or in the form of a pill or 
tablet [1]. Low-cost processing involving mild conditions to maintain the antigenicity of the expressed protein were to be used to make oral vaccines with 
increased shelf life under a wider range of normal storage conditions [8].  
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A major hurdle for the oral delivery of any pharmaceutical is the digestive system degrading and 
digesting the protein before it can carry out its function. As a result, there can be significant variation 
in  the  quantity  of  antigen  delivered  to  the  immune  system,  necessitating  administration  of  larger 
amounts of the vaccine formulation in order to offset the loss of antigens. The variability of responses 
between  candidates,  the large  amount of antigen required,  the concern regarding  potentiating  oral 
tolerance [9], and the continued concern of contamination of the food chain with pharmaceuticals led 
to the development of plant-based pharmaceuticals that are largely produced in non-food crops such as 
tobacco and are then highly purified for parenteral delivery. Presently there has been acceptance of 
recombinant,  pharmaceutical  proteins  purified  from  plant  sources  for  use  in  human  clinical  trials 
including Phase III [10–12], an extensive list of which is presented by Paul and Ma [13]. Dosage and 
quality  control  of  these  plant-made  pharmaceuticals  are  controlled  in  a  manner  similar  to  their 
traditional counterparts.  
3. Current Status of Plant-Made Pharmaceuticals 
3.1. Plant-Made Vaccines 
A search of the literature for plant-made antigens or vaccines results in multiple hits describing the 
expression of many different vaccine antigens in many different plant systems. It is not the ability of plant 
systems to express antigens that needs to be demonstrated to the wider protein production community, but 
rather the efficiency and efficacy of the resulting proteins. Further, the systems need to gain safety and 
regulatory approval, and demonstrate the capacity for economical production at large scales. 
Originally, the major perceived disadvantage of the plant-made recombinant protein platform was 
its inability to compete with other recombinant protein production platforms with regards to the level 
of recombinant protein produced and the time taken to produce it. Compared to other platforms such as 
bacteria or animal cells, plants produced at least 10-fold less protein of interest, and it could take up to 
18 months to produce a stably transformed plant line. However, this situation has become outdated 
with the refinement of transient plant transformation systems. Agroinfiltration can be used to deliver 
minimal, deconstructed plant virus-based expression vectors, such as the system based on a disabled 
cowpea  mosaic  virus  RNA-2  by  Sainsbury  and  colleagues  [14]  or  the  ―magnifection‖  system 
developed by Icon Genetics [15,16] , which has resulted in recombinant protein accumulating up to 
80% of total soluble protein (TSP) in tobacco leaves [15].  
D’Aoust et al. [17,18] made an important step with regards to utility of plant-based vaccines by 
demonstrating plants capable of acting as rapid response production systems. Protective antigens of 
multiple  strains  of  influenza  were  transiently  expressed  in  Nicotiana  benthamiana  using  an 
Agrobacterium-mediated,  transient  expression  system.  The  agro-infiltrated  plants  produced  large 
amounts of protective antigen (50 mg/kg) from H5N1 (AIV) and H1N1 (human) strains. However the 
pertinent detail was that this was performed in less than three weeks from release of viral sequence to 
purified  vaccine  product.  Thus  this  rapid  vaccine  production  system  would  prove  valuable  in 
protecting against disease outbreaks and in enabling expedient mobilisation of personnel. The above 
mentioned plant-made influenza vaccine has completed Phase II human trials. Fraunhofer USA, Inc. 
has also used a transient plant transformation system to go from recently released H1 HA sequence to 
grams of purified protein in less than a month [19]. While these products would still have to acquire Int. J. Mol. Sci. 2011, 12                    
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regulatory approval before use, this is also the case for current vaccines. Initial products would likely 
have to go through more rigorous trials, however once the safety of the platform is confirmed there is 
no reason that regulatory approval would take longer that for current technologies. 
Recent advances in stable systems have resulted in much higher levels of recombinant protein 
accumulation. Utilization of sub-cellular targeting and chloroplast transformation has resulted in levels 
of up to 46% TSP being reported [20]. Stable expression of recombinant proteins such as vaccine 
antigens has also been actively pursued in seeds crops such as rice and maize, as these platforms 
produce high yields and are easy to scale up. Another benefit of seeds is their inherently stable nature. 
For  example,  a  rice-based  cholera  vaccine,  MucoRice-CTB,  was  shown  to  be  stable  at  room 
temperature for 18 months, as well as being resistant to pepsin digestion [21]. This was later shown to 
be stable for up to three years, and gave protection to mice against both cholera and enterotoxigenic 
Escherichia coli (ETEC) [22]. Likewise, an ETEC subunit vaccine produced in soybean seeds was 
found  to  be  stable  over  four years,  as  well  as when  formulated into soymilk  [23]. The problems 
associated with seed systems are largely down to regulatory issues, as containment can be problematic 
with wind dispersal and seeds can remain viable in the soil after the crop has been harvested. Also, 
especially with crops such as rice and maize that are a staple food source for many, the potential for 
unwanted transgenes to enter the food supply could have major repercussions. However, these risks 
can be managed through the spatial and temporal segregation of crops as well as other physical and 
biological segregation techniques [24]. Chloroplast transformation can address some of these concerns 
regarding foreign gene transfer via pollen, due to the maternal inheritance of transgenes [25]. The 
potential for large-scale use of seed crops depends largely on the containment requirements decided on 
by regulatory agencies. 
3.2. The Successful Plant-Made Vaccine 
The  world’s  first  licensing  of  an  (injectable)  plant-made  vaccine  occurred  in  early  2006  
(Figure 1) [26]. On 31 January 2006, Dow AgroSciences LLC announced that it had received the 
world’s  first  regulatory  approval  for  a  plant-made  vaccine  from  the  United  States  Department  of 
Agriculture. The developed plant-made vaccine combats Newcastle Disease Virus (NDV) and was 
made using a contained, plant-cell culture production system. A transgenic tobacco plant cell line that 
was  grown  as  a  suspension  culture  in  a  conventional  bioreactor  system  was  used  to  produce  the  
plant-made  NDV  vaccine.  Using  this  system,  large  quantities  of  vaccine  can  be  produced  in  the 
bioreactor system in a relatively short time period of a few weeks. The resulting cells are harvested and 
minimally processed to provide a partially purified antigen for formulation into the final vaccine. Birds 
vaccinated  subcutaneously  with  the  plant-made  vaccine  were  protected  against  lethal  challenge  to 
NDV [27]. While this was never brought forward to a commercially available product, the formulation 
was advanced through the USDA Center for Veterinary Biologics’ regulatory approval, demonstrating 
that plant-made vaccines could be developed within the existing regulatory framework. 
3.3. Plant-Made Antibodies 
As with plant-made vaccine antigens, there are many reports of plant-made antibodies in the literature, 
with  applications  ranging  from  diagnostics  [28–31];  tumor  targeting  or  cancer  treatment  [32–37]; Int. J. Mol. Sci. 2011, 12                    
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prevention  of  tooth  decay  [38–40];  prevention  of  plant  disease  [41,42];  and  preventing  sexually 
transmitted  disease  [43–45]  (see  De  Muynck  et  al.  [46]  for  a  comprehensive  review).  Different 
subclasses have been expressed (IgG, sIgA, IgM [46]) in different plant species however Nicotiana 
species (N. tabacum 58.1% or N. benthamiana 16.3%) dominate (74.4% total). 
The  refinement  of  transient,  deconstructed  plant  viral  transformation  systems  advanced  the  
plant-made  antibody  field  by  allowing  rapid  and  high-yield  production  of  complex  recombinant 
proteins such as antibodies. Initial attempts at the co-transformation of plant cells with multiple copies 
of the same virus vector containing different proteins (or different antibody fragments) resulted in the 
spatial separation of the different viral populations in the infiltrated tissues. However, Giritch and 
colleagues  [47]  solved  this  dilemma  through  using  non-competing  viral  vectors  such  as  tobacco 
mosaic virus and potato virus X. 
Advanced plant and mammalian glycosylation differ in regards to the types of sugar moieties added 
and the types of linkages [48]. While this difference was not of consequence to the success of the 
plant-made antibodies described later, it is thought that this difference in glycosylation may result in 
the  original  problem  with  antibodies  of  non-human  origin  being  seen  as  antigenic  by  the  
patient  [49,50]. There is also some evidence  that plant specific glycosylation  motifs can elicit  an 
immune  response.  However,  plants  have  recently  been  genetically  modified  to  mimic  the  typical 
animal glycosylation pattern thus preventing potential problems [46]. This was achieved by either 
inactivating  native  enzymes  responsible  for  glycosylation  [51,52],  or  by  expressing  heterologous 
enzymes responsible for mammalian-like glycosylation [53]. 
3.4. Successful Plant-Made Antibodies 
Two plant-made antibody products have made it to human clinical trials. Planet Biotechnology Inc. 
produced  the  world’s  first  clinically  tested  antibody,  CaroRx™  in  tobacco.  CaroRx™  specifically 
binds to the bacteria that cause tooth decay thereby preventing adhesion of the bacteria to teeth [54]. 
CaroRx™  is  currently  undergoing  Phase  II  U.S.  clinical  trials  under  a  U.S.  Food  and  Drug 
Administration-approved Investigational New Drug application (Figure 1).  
In July 2008 Large Scale Biology Corp. reported the success of the first human clinical trials testing 
a plant-made vaccine directed against cancer [55] (Figure 1). A transient, plant viral expression system 
produced  patient-specific,  recombinant,  idiotype  vaccines  against  follicular  B  cell  lymphoma  in 
tobacco. The vaccine was produced and purified within 12–16 weeks of receiving biopsy specimens 
before testing in a Phase I safety and immunogenicity clinical trial. Sixteen patients immunized with 
their  own,  individual  therapeutic  antigen  showed  no  serious  adverse  effects  yet  70%  of  patients 
developed  cellular  or  humoral  immune  responses  and  47%  developed  antigen-specific  responses. 
Evidence  was  found  that  in  this  circumstance,  immune  responses  were  not  directed  toward  
plant-specific glycan structures (glycosylation) but rather to the idiotype sequence itself. In December 
2009  Bayer  started  the  clinical  development  of  this  plant-made  antibody  vaccine,  successfully 
submitting a Phase I study protocol to the US FDA (United States Food and Drug Administration).  
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3.5. Additional Plant-Made Therapeutic Proteins 
As is the case with antibodies, protein therapeutic use is limited by the shortfall in manufacturing 
capacity the high cost of production. Driven by our aging population, the 2003 market for therapeutic 
proteins grew by almost 19%, with predicted 2010 sales of over $90 billion [56]. The potential for 
future growth is dependent largely on the industry overcoming drug delivery challenges and cost issues. 
As demonstrated by antibody production, plants excel at producing complex and ―hard-to-make‖ 
therapeutic  proteins.  There  have  been  many  reports  of  therapeutic  protein  expression  in  plants, 
including anticoagulants [57]; thrombin inhibitors [57]; growth hormones [58]; blood substitutes [57,59]; 
collagen  replacement  [60];  antimicrobial  agents  [61];  and  for  treatment  and/or  prevention  of 
neutropenia [62]; anemia [63]; hepatitis [57,64]; liver cirrhosis and burns [63]; cystic fibrosis, liver 
diseases and hemorrhage [62]; hypertension [62]; HIV [62]; diabetes [65]; Gaucher’s disease [11]; and 
organophosphate poisoning [66]. As with the previously described plant-made pharmaceuticals, the 
increase  in  recombinant  protein  produced  due  to  the  use  of  transient,  deconstructed  viral  based 
expression  systems  has  improved  the  likelihood  of  using  plants  as  therapeutic  protein  production 
systems [67]. The low risks associated with some therapeutic proteins may also require less stringent 
containment,  allowing  seed  crops  to  be  grown  on  a  large  scale  to  produce  large  volumes  of  
high-demand proteins.  
3.6. Successful Plant-Made Therapeutics 
The first report of a plant-made therapeutic (PMT) protein reaching Phase II human clinical trials 
was made by Biolex Therapeutics, Inc. regarding Locteron (Figure 1), a plant-made, controlled release, 
interferon  alfa  (IFN-α)  treatment  for  chronic  hepatitis  C  [64].  The  current  treatment  of  patients 
involves weekly administration of an IFN-α in combination with an antiviral drug. Unfortunately the 
antiviral  drug  (Ribavirin)  is  associated  with  significant  side  effects  [68].  In  2005,  32  patients 
participated in Phase IIa clinical trials of Locteron. The IFN-α produced in the aquatic plant Lemna 
was administered fortnightly in combination with ribavirin in a randomised double blind study. An 
early virologic response was achieved by 100% (16/16) of hepatitis C patients treated with 480 and 
640  µg   doses.  This  is  of  importance,  as  early  virologic  responses  have  been  established  to  be  a  
pre-requisite for long-term response in hepatitis C patients. Phase IIb trials have since been performed 
with  the  results  being  released  on  March  31,  2011  at  the  46th  Annual  Meeting  of  the  European 
Association for the Study of the Liver (EASL) in Berlin [69]. 
The first plant-made therapeutic directed for human use to reach Phase III clinical trials was a carrot 
cell  suspension  derived,  Gaucher’s  disease  therapeutic  (Figure  1)  developed  by  Protalix 
BioTherapeutics. The transgenic carrot cells expressed human glucocerebrosidase (human prGCD) and 
were grown as a cell suspension in a bioreactor system. The carrot cell suspension produced proteins 
that  had  consistent  batch-to-batch  enzymatic  activity  of  a  highly  active  product.  The  purified 
recombinant protein was tested in Phase I/II trials in 2006 [11] before entering Phase III trials in  
2009 [70]. Thirty-one naive patients suffering from Gaucher disease were tested in a multi-centre, 
randomised, double blind trial. The primary endpoint (20% mean reduction from baseline in spleen 
volume) was achieved in prGCD treatment groups after only 6 months of therapy and furthermore the 
safety analysis showed that prGCD was well tolerated and no serious or severe adverse events were Int. J. Mol. Sci. 2011, 12                    
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reported. Patients who successfully completed this study were granted expanded access some for over 
two and a half years. On December 1, 2009, Pfizer and Protalix entered into an agreement to develop 
and  commercialise  prGCD  for  the  treatment  of  Gaucher’s  disease.  The  agreement  gives  Pfizer 
exclusive  worldwide  licensing  rights  while  Protalix  retains  commercialization  rights  in  Israel. 
However, in early 2011 the FDA declined approval for the drug, asking for additional data from 
existing studies, but not requiring any additional trials.  
SemBioSys have also completed a phase I-II trial of safflower-produced insulin, and found it to 
have a similar safety profile to current recombinant insulin [71]. The insulin is produced in oil bodies 
allowing for simplified extraction, and the plants have been grown in open fields. Also using seed 
crops, although this time in contained greenhouses, ORF Genetics produces various growth factors and 
cytokines in transgenic barley for use in cosmetics. 
4. Comparing Development of Different Recombinant Production Systems 
It can thus be seen that while plant-made vaccines have progressed at a relatively slow rate of 
development (Figure 1), the system has reached important milestones seen in the development of other 
pharmaceutical production systems. The most commonly used system for expression of recombinant 
protein is Escherichia coli. It was the first expression system introduced, with the pioneering work 
being  undertaken  by  Stanley  Cohen  and  colleagues  in  1973,  who  demonstrated  that  a  gene  for 
ribosomal RNA from the South African clawed frog could be incorporated into and expressed by  
E. coli [72]. In terms of speed, bacterial cell cultures grow faster than insect cells, mammalian cells or 
yeast. However, they are unable to glycosylate proteins. For products where this is of importance, the 
problem  can  be  overcome  with  the  use  of  mammalian  cells.  Since  their  introduction  in  the  
mid-1970s [73], mammalian cell culture has become the second most used production system. This is 
despite inherent drawbacks to the system, including high fermentation costs, slow growth and the risk 
of viral infection. However, the history of non-recombinant mammalian cell cultures extends further 
back, with early developments in cell culture techniques driven by the need for an in vitro cell system 
for associated fields, such as virology and cell biology. For example, the first systematic review of cell 
culture conditions was in 1955 [74].  
The main advantages of using yeast species such as Saccharomyces cerevisiae and Pichia pastoris 
for  the  production  of  recombinant  pharmaceuticals  are  related  to  the  fact  that  yeast  is  both  a 
microorganism  and  a  eukaryote.  Yeast  production  systems  have  relatively  high  yields  and  low 
fermentation costs in comparison to mammalian systems, and as an additional benefit, and in contrast 
to E. coli, when yeast signal sequences are used, yeast species can secrete correctly folded and fully 
functional proteins into the medium, greatly decreasing the cost of purification [75]. However, for the 
production of glycoproteins, native high-mannose yeast glycosylation is not suitable for human use 
and  represented  a  major  limitation  for  yeast-based  production  systems  before  the  development  of 
glycoengineered yeast lines capable of producing humanised sialylated glycoproteins [76]. A relative 
newcomer to the protein production field is the baculovirus expression vector (BEV), a eukaryotic 
DNA  viral  vector  that  infects  lepidopteran  insect  cells.  While  able  to  perform  post-translational 
modifications of proteins, insect glycosylation is much simpler than that of mammalian cells. 
The ultimate test of a production system is whether a product developed can be utilised in a clinical 
setting or as a veterinary product. As part of the transition from research laboratory to clinical trial, the Int. J. Mol. Sci. 2011, 12                    
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product  must  receive  the  approval  from  pharmaceutical  regulatory  departments.  There  are  three 
categories  of  products;  diagnostic  reagents,  therapeutics  and  vaccines,  each  with  its  own  set  of 
conditions  and  regulations.  The  progress  and  applications  of  plant-derived  pharmaceuticals  as 
compared to insect, mammalian, E. coli and yeast is summarised in Figure 1. Cervarix, a bivalent 
vaccine against the human papillomavirus manufactured by GlaxoSmithKline, was the first vaccine 
made in insect cells to receive FDA approval in 2009. The use of insect cells as a production system 
for  recombinant  protein  was  first  shown  to  be  viable  in  1983  [77],  over  25  years  before  any 
recombinant protein pharmaceutical product received approval, and close to a decade before plant 
production was reported (Figure 1). It is worth noting that to date, no veterinary product produced in 
an insect production system has been granted regulatory approval. 
The development of plant-made human and veterinary vaccines is an important step to concrete 
plant-based  technology.  The  first  human  trials  for  a  plant-derived  vaccine  were  performed  in  
1997 [78]. Since that time, many products produced in plants have entered clinical trials and their 
efficacy tested.  
The classes of drugs that face the greatest difficulty in receiving regulatory approval are human 
vaccines  and  therapeutics.  The  long,  complicated  and  expensive  process  is  designed  to  screen  all 
potential new pharmaceuticals and to safe guard the public from drugs that have not been adequately 
researched. Any expression system used must be well characterized. As a result, many products do not 
reach  clinical  trial.  The  intricacy  of  the  process  and  the  costs  involved  often  discourage  smaller 
companies from investigating new pharmaceuticals. The production centers must meet strict standards 
for GMP, and Standard Operating Procedures must be developed and followed. While no plant-made 
human vaccine or therapeutic has as yet received regulatory approval, Protalix BioTherapeutics and 
Pfizer’s prGCD for the treatment of Gaucher’s disease has been granted Orphan drug designation and 
Fast  Track  status  by  the  FDA.  These  achievements  illustrate  the  ―coming  of  age‖  of  plant-based 
pharmaceutical manufacturing. Together with the approval of a veterinary vaccine, they illustrate that 
there is nothing about plant-based systems that poses insurmountable obstacles at the regulatory level. 
Bibliographic analysis has shown that after 20 years of active research, there has been no decline in 
publication activity related to plant-derived pharmaceuticals [10]. However it has been demonstrated 
many  times  that  there  is  no  universal  recombinant  production  system  that  can  guarantee  high 
expression of a particular recombinant pharmaceutical, and as a result the choice of system will have 
to be approached on a case-by-case basis.  
5. The Future of Plant Made Pharmaceuticals 
The benefits of plant made pharmaceuticals have been pointed out repeatedly in the literature, with 
reviews on the technology and its advantages far outnumbering reviews on other systems. However, 
the  technology  is  only  now  starting  to  be  implemented  due  to  investment  by  big  pharmaceutical 
companies, such as Pfizer with prGCD, who have the funds and experience to deal with regulatory 
agencies needed to reach market approval. Once the infrastructure is in place for these ventures, it may 
become more common for plant systems to be the preferred method of protein production in the future. 
Now that plant made pharmaceuticals are approaching the market, it is perhaps a good time to look to 
the  future  of  the  technology.  By  looking  at  what  can  be  achieved  now  and  planning  for  future Int. J. Mol. Sci. 2011, 12                    
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developments, the momentum that has slowly been building up to this point can be continued into 
new areas.  
Plant-based systems have shown themselves able to reproduce a wide variety of human proteins. 
Beyond basic single peptide production, proteins that consist of multiple proteins have been produced 
and assembled in plants [38] as well as proteins requiring the co-expression of additional modifying 
enzymes  [79],  and  indeed,  entire  synthesis  pathways  are  now  being  transformed  [80].  Unwanted 
posttranslational  modifications  can  also  be  prevented  by  shutting  down  native  modification  
pathways [51]. While retention of glycosylated protein in the endoplasmic reticulum has been used to 
prevent the plant specific glycosylation that occurs in the Golgi body, this method is not absolute, as 
some proteins pass through to the Golgi body before being recycled back to the endoplasmic reticulum 
(ER). This results in small, but detectable, quantities of protein with plant specific glycosylation [81] 
The trend towards producing increasingly complex molecules is likely to continue, requiring both 
the expression of a precursor protein as well as the addition of modification pathways. Furthermore, 
target proteins may be modified by the addition of extra functional domains, altered sequences or 
optimized glycosylation to increase bioactivity or stability. For example, a human IgG produced in 
moss  lacking  plant  specific  N-glycosylation  possessed  a  40-fold  increase  on  antibody-dependent 
cellular cytotoxicity compared to the mammalian version [82]. This is an area of great potential that is 
opening up as our understanding of molecular interactions increases. 
While there has been a lot of work done on enhancing the transformation capabilities of plants, with 
many vectors being designed with various advantages and disadvantages [83], very little research has 
been done into optimizing the plants themselves. As plant bio-factories become more common, it 
seems an important next step is to optimize the plants used, and identify the conditions that suit the 
expression of specific proteins. 
These optimizations can result from two mechanisms; by adjusting the conditions the plants are 
grown  in  or  by  genetically  modifying  the  host  plants.  For  example,  there  is  a  vast  array  of 
environmental factors that can affect the growth and metabolism of plants, and for the most part, these 
can  be  easily  regulated  [84].  However,  there  have  been  few  studies  on  what  the  optimal  growth 
conditions are for protein production, as opposed to plant growth. Certain promoters are more or less 
active under certain conditions, and the plant’s metabolism may vary greatly across environments [85]. 
Currently,  whole  plants  are  grown  in  conditions  optimal  for  vegetative  growth,  although  these 
conditions may not be ideal for transgene expression and accumulation. This may also differ between 
stable or transient production, as well as in response to tissue specific expression. Important factors 
may include photoperiod, light intensity, temperature, nutrient availability, humidity, carbon dioxide 
concentration and others, as well as interactions between them. Varying conditions may also be better 
suited to different stages of plant growth, from seedling to harvest. It is likely that expression levels 
could be boosted in many systems simply by adjusting these factors. 
The  second  pathway  for  optimization  is  more  likely  to  progress  with  the  aid  of  larger 
biopharmaceutical  companies.  This  entails  the  optimization  of  the  plants  themselves  so  that  their 
characteristics are more amenable to producing recombinant proteins, such as modifying the metabolic 
pathways to produce human glycosylation patterns [53,86]. Harmful or disruptive native proteins can 
also be removed or down regulated. There is also a strong case for the addition of marker genes or 
DNA sequences to be included in transgenic plants, such as fluorescent proteins, which will allow the Int. J. Mol. Sci. 2011, 12                    
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rapid and simple identification of recombinant plants in suspected escape cases [87]. Modifications can 
also be made to the life history of the plant, including delaying or preventing flowering, increasing leaf 
or fruit biomass, increasing growth rates, or adjusting the plants height. While terminator genes are 
frowned  upon  for  agricultural  GM  plants,  such  a  system  would  be  ideal  for  recombinant  protein 
production to prevent transgenes escaping into the wild.  
The original idea of plant made vaccines was the ability to vaccinate someone by eating a piece of 
fruit or vegetable. However, recombinant plant proteins are currently only used after being highly 
purified. While raw edible vaccines are currently an unfeasible technology for human vaccines and 
therapeutics, it may not be necessary to fully isolate the target protein from plant material. A middle 
ground  consisting  of  dried  and  ground  plant  material  would  be  suitable  for  the  oral  delivery  of 
vaccines and some therapeutics, and also allow for batch testing and analysis. In this case, a balance 
would have to be found between achieving the correct dose of vaccine while reducing the amount of 
any detrimental compounds. This could be greatly helped by optimizing the host plant’s characteristics 
with regard to the amount of detrimental metabolites it contains. Such oral vaccines could be produced 
cheaply and easily for use in developing nations [88]. This would also be an excellent option for the 
production of veterinary vaccines where recombinant feed could contain vaccine antigens. If yields can 
be better standardized, there is potential for the delivery of therapeutics in unprocessed plant material, 
especially for veterinary purposes or for products where the dosage has a wide active range. However, 
that would be not be a realistic option until wholly and partially purified products are on the market 
and shown to be safe and effective. It is likely that partially purified vaccines will first be introduced 
for  veterinary  purposes  and  then  progress  to  humans  once  the  technology  gains  acceptance.  It  is 
important that innovation continues in the field of plant-made pharmaceuticals and vaccines in order to 
confirm the technology’s potential to become a major platform for recombinant protein productions. 
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